Literature DB >> 2579105

Blood group antigens A, B, H, Lea, Leb, and I(Ma) in resting and tetragastrin stimulated gastric juice of patients with non-neoplastic diseases of the stomach.

J K Picard, K Hotta, T Feizi.   

Abstract

In view of the anomalous expression of blood group and related antigens in the gastric mucosae of patients with malignant and premalignant diseases of the stomach, and the potential clinical value of their measurement, a preliminary study has been performed on the blood group antigens A, B, H, Lea, Leb, and I(Ma) in glycoprotein rich extracts of the resting and tetragastrin stimulated gastric juice of patients without evidence of gastric cancer. The aim has been to assess whether the antigenic profiles known to distinguish the gastric mucosae of secretors from those of non-secretors are reflected in the glycoproteins of gastric juice. Antigenic profiles which distinguish secretors from non-secretors were observed in the stimulated rather than the resting gastric juice as follows: the A, B or H antigens but not I(Ma) were strongly expressed in the glycoproteins of secretors, while I(Ma) was the antigen characteristic of non-secretors. On the other hand, there was considerable overlap in the Lea and Leb antigen values in the resting and stimulated gastric juice of secretors and non-secretors. Among these antigens, I(Ma) is known to appear as a neo-antigen in the gastric mucosae of secretors with malignant and premalignant diseases of the stomach. Thus this antigenic determinant is potentially a clinically useful marker in the gastric juice of 75% of the population who are secretors. The clinical value of the levels of this antigen in the gastric juice now deserves investigation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579105      PMCID: PMC499134          DOI: 10.1136/jcp.38.3.320

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  The recognition of water-soluble I blood group substance.

Authors:  W Dzierzkowa-Borodej; H Seyfried; M Nichols; M Reid; W L Marsh
Journal:  Vox Sang       Date:  1970-03       Impact factor: 2.144

Review 2.  Chemistry, distribution, and function of blood group substances.

Authors:  A E Szulman
Journal:  Annu Rev Med       Date:  1966       Impact factor: 13.739

Review 3.  Biochemistry and Genetics of the ABO, Lewis, and P blood group systems.

Authors:  W M Watkins
Journal:  Adv Hum Genet       Date:  1980

4.  Monoclonal antibodies point to carbohydrate structures as tumour-associated antigens.

Authors:  T Feizi
Journal:  Med Biol       Date:  1983-06

Review 5.  Gastrointestinal mucins. Structures and antigenicities of their carbohydrate chains in health and disease.

Authors:  E F Hounsell; T Feizi
Journal:  Med Biol       Date:  1982-10

Review 6.  Blood group antigens and gastric cancer.

Authors:  T Feizi
Journal:  Med Biol       Date:  1982-02

7.  Immunochemical studies on the combining site of the blood group H-specific lectin 1 from Ulex europeus seeds.

Authors:  M E Pereira; E C Kisailus; F Gruezo; E A Kabat
Journal:  Arch Biochem Biophys       Date:  1978-01-15       Impact factor: 4.013

8.  A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II.

Authors:  J L Magnani; B Nilsson; M Brockhaus; D Zopf; Z Steplewski; H Koprowski; V Ginsburg
Journal:  J Biol Chem       Date:  1982-12-10       Impact factor: 5.157

9.  A marker of human foetal endoderm defined by a monoclonal antibody involves Type 1 blood group chains.

Authors:  H C Gooi; L K Williams; K Uemura; E F Hounsell; R A McIlhinney; T Feizi
Journal:  Mol Immunol       Date:  1983-06       Impact factor: 4.407

10.  Immunocytochemical studies of blood group A, H, I, and i antigens in gastric mucosae of infants with normal gastric histology and of patients with gastric carcinoma and chronic benign peptic ulceration.

Authors:  A Kapadia; T Feizi; D Jewell; J Keeling; G Slavin
Journal:  J Clin Pathol       Date:  1981-03       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.